Navigation Links
Genmab Announces HuMax-CD32b Pre-Clinical Program
Date:1/4/2008

eams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Roche Files IND for Second Genmab Antibody
2. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
3. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
4. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
5. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
6. Genmab Announces Results for the First Nine Months of 2007
7. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
8. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
9. Genmab A/S - Company Announcement
10. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
11. Genmab Announces Asset Exchange Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 02, 2015 Research and Markets ... "Bioburden Testing Market by Product , Test, Application ... to their offering. The bioburden testing market ... $354.4 Million in 2014, growing at a CAGR of ... of products, the microbial limit testing market is segmented ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/2b7734/molecular ) has announced the addition ... Strategy and Forecasts - 2015 to 2019" report ... Market Size, Strategy and Forecasts - 2015 to 2019" ... of pages of information including a complete list of ... help understand test pricing in detail. See ...
(Date:6/2/2015)... Meet ARGUS, The World,s First ... Read People. Analyze emotions and predict actions. Explore a ... very first Responsive-RPG: "The Eye: Genesis".      ... , , https://www.youtube.com/watch?v=B1ZEtAZ2Yf8 ... inner feelings - and those of others. Being able ...
(Date:6/2/2015)... 02, 2015 Cirrascale Corporation ... and rackmount computing and storage infrastructure for conventional ... of its high density scale-out, two-in-one video delivery ... RM1622D . The high density, two-in-one system supports ... family with Intel® Iris™ Pro graphics P6300 and ...
Breaking Biology Technology:Bioburden Testing Market 2015 - Global Forecasts to 2019 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 3ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3
... at the U.S. Department of Energy,s Lawrence Berkeley National ... demonstrated a way to fabricate efficient solar cells from ... active semiconductors in arrays of nanoscale pillars, each a ... meter. "To take advantage of abundant solar ...
... has named Neogen Corporation (Nasdaq: NEOG ) as ... small public companies (FSB 100). , , In announcing its ... the FSB 100 constitutes an elite group of small public companies: ... performance over the past three years. But in this Great Recession, ...
... 9 Harvest Technologies Corp. ( www.harvesttech.com ... trial conducted at Sri Ramachandra Medical Center in Chennai, ... with non-reconstructable Critical Limb Ischemia (CLI) has completed ... Medical international-associated institution based in Chennai, India and one ...
Cached Biology Technology:Nanopillars promise cheap, efficient, flexible solar cells 2Nanopillars promise cheap, efficient, flexible solar cells 3Neogen Named to Fortune's List of Fastest Growing Companies 2Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
(Date:5/27/2015)... CLEVELAND , May 27, 2015 /PRNewswire/ ... in medication safety systems and image documentation ... provider of comprehensive, technologically-advanced automation solutions, is ... art integration. The Codonics® Safe Label System® ... used in conjunction with the Omnicell Anesthesia ...
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3
... currently underway has created a rare opportunity to study the ... rain forest habitats. Dr. Amy Berkov, Professor of Biology ... a research effort that could shed new light on biodiversity ... to study biodiversity and conservation, you need to know what ...
... of forests may have been the primary cause of the ... and cave lion, according to Durham University scientists. The ... beings were the primary cause of the extinction of mammals ... The research is part of the most comprehensive study ...
... Alzheimer,s disease destroys brain cells and their connections (called ... disrupt work, hobbies and daily life. Symptoms can be ... the United States as Namenda), which is currently FDA-approved ... developed by Stuart A. Lipton, M.D., Ph.D., Director of ...
Cached Biology News:CCNY biologists study rainforest host-plant associations 2CCNY biologists study rainforest host-plant associations 3Dwindling green pastures, not hunting, may have killed off the mammoth 2Dwindling green pastures, not hunting, may have killed off the mammoth 3Study explains why Alzheimer's drug is both safe and effective 2
... collects data from balances and scales with RS232 ... other program. If you can type the weight ... collection process Simple to use parser extracts ... , Add user information , Collect data at ...
...
Mitochondria/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
Biology Products: